“The turnover of Humana’s senior management team continues to play out as CFO Jim Bloem announced that he will retire at the end of the 2013. This follows the retirement of former CEO Mike McCallister at the end of 2012. Mr. Bloem captured the entire upcycle in MA during his tenure as CFO and now could be exiting right in front of a potential MA downturn that could begin in 2014 based on the highly challenging prelim 2014 MA rate proposal. We continue to see elevated EPS headwinds for the MCO industry in 2014 and reduce our PT for HUM to $68 from $80.,” the firm’s analyst commented.
Shares of Humana traded down 0.72% during mid-day trading on Tuesday, hitting $68.715. Humana has a one year low of $59.92 and a one year high of $93.36. The stock’s 50-day moving average is currently $74.16. The company has a market cap of $10.881 billion and a P/E ratio of 9.27.
The company also recently declared a quarterly dividend, which is scheduled for Friday, April 26th. Shareholders of record on Thursday, March 28th will be given a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 1.50%.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group reiterated a buy rating on shares of Humana in a research note to investors on Tuesday. They now have a $93.00 price target on the stock. Separately, analysts at S&P Equity Research downgraded shares of Humana from a strong-buy rating to a buy rating in a research note to investors on Wednesday, February 20th. Finally, analysts at S&P Equity Research cut their price target on shares of Humana from $90.00 to $80.00 in a research note to investors on Wednesday, February 20th.
Eleven analysts have rated the stock with a buy rating, two have issued an overweight rating, seven have issued a hold rating, and one has given a sell rating to the stock. Humana has a consensus rating of overweight and an average price target of $83.87.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.